Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 5,228 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Germ Cell Tumor Clear all
Terminated No phase listed Observational

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

NCT03407040
View directory record Official record
Conditions
Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer, Melanoma, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 21, 2026, 10:16 AM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

NCT07338968
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Observational
Other
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
10
States / cities
Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

NCT04123470
View directory record Official record
Conditions
Malignant Melanoma
Interventions
delolimogene mupadenorepvec, atezolizumab
Genetic · Biological
Lead sponsor
Lokon Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 1 Interventional

A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815
View directory record Official record
Conditions
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
Interventions
VET3-TGI, Atezolizumab
Drug
Lead sponsor
KaliVir Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

NCT05366179
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Months to 24 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Not applicable Interventional

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

NCT05373823
View directory record Official record
Conditions
Melanoma
Interventions
MySmartSkin enhancement, Educational webpage on Skin Self-Examination, Assess implementation outcomes
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1 Interventional

Dendritic Cell Activating Scaffold in Melanoma

NCT01753089
View directory record Official record
Conditions
Melanoma
Interventions
WDVAX
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

NCT00045110
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Recurrent Adult Brain Tumor
Interventions
erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 1 Interventional

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

NCT03500991
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
Interventions
HER2-specific chimeric antigen receptor (CAR) T cell
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2039
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Not yet recruiting Phase 1 Interventional

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT07422896
View directory record Official record
Conditions
Glioblastoma
Interventions
B-cell vaccination
Biological
Lead sponsor
Catalina Lee Chang
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 2 Interventional

Venous Thromboembolism Prevention in Outpatients With Glioma

NCT05683808
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

NCT01525550
View directory record Official record
Conditions
Well-differentiated Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 3 Interventional

Fluorescence-guided Surgery for Low- and High-grade Gliomas

NCT01502280
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevulinic acid (ALA), Placebo - ascorbic acid
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 21, 2026, 10:16 AM EDT
Completed No phase listed Observational

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

NCT03438279
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 21, 2026, 10:16 AM EDT
Terminated Phase 1 Interventional

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

NCT02880410
View directory record Official record
Conditions
Glioblastoma
Interventions
NeuroBlate System, Radiation therapy and temozolomide
Device · Drug
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
St Louis, Missouri • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 21, 2026, 10:16 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer

NCT04099446
View directory record Official record
Conditions
Skin Cancer, Melanoma (Skin), Squamous Cell Carcinoma, Basal Cell Carcinoma, Microbiome
Interventions
Non-interventional
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1 Interventional

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

NCT00005860
View directory record Official record
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 21, 2026, 10:16 AM EDT
Terminated Phase 2 Interventional

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

NCT00121420
View directory record Official record
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting No phase listed Observational

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

NCT03728842
View directory record Official record
Conditions
Melanoma; Renal Cell Carcinoma
Interventions
Blood collection for laboratory studies, Data collection from medical record
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Results available

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

NCT02032810
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Panobinostat, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 21, 2026, 10:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Experience of Brain Tumor Caregivers

NCT00352820
View directory record Official record
Conditions
Brain Cancer, Glioma
Interventions
Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 21, 2026, 10:16 AM EDT